NEW YORK, May 8, 2017 /PRNewswire/ --
Stock-Callers.com today presents four Medical Appliances and Equipment companies for assessment: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Neovasc Inc. (NASDAQ: NVCN), Wright Medical Group N.V. (NASDAQ: WMGI), and Sunshine Heart Inc. (NASDAQ: SSH). These stocks operate in the Healthcare sector, which has received an "Outperform" rating from Charles Schwab on April 27th, 2017 due to increased need for health care services and strong financials. Register now and get full and free access to our downloadable research reports on these stocks at:
Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc.'s shares recorded a trading volume of 1.50 million shares last Friday, above their three months average volume of 1.15 million shares. The stock finished the trading session 0.27% lower at $116.54. The Company's shares have gained 13.15% since the start of this year. The stock is trading below its 200-day moving average by 0.99%. Furthermore, shares of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, Middle East, Africa, and Asia/Pacific, have a Relative Strength Index (RSI) of 39.91.
On April 27th, 2017, Zimmer Biomet reported financial results for the quarter ended March 31st, 2017. The Company reported Q1 2017 net sales of $1.98 billion, diluted earnings per share (EPS) of $1.47, adjusted diluted EPS of $2.13, net earnings of $299.4 million, and operating cash flow of $275.4 million. In addition, the Company paid $48.1 million in dividends, and declared a Q1 dividend of $0.24 per share.
On April 28th, 2017, research firm Needham reiterated its 'Strong Buy' rating on the Company's stock with an increase of the target price from $151 a share to $153 a share. Access our complete research report on ZBH for free at:
On Friday, Richmond, Canada headquartered Neovasc Inc.'s stock ended the session 1.34% higher at $1.51. A total volume of 94,798 shares was traded. The Company's shares have gained 14.39% over the previous three months. The stock is trading 36.08% above its 200-day moving average. Moreover, shares of Neovasc, which develops, manufactures, and markets cardiovascular products worldwide, have an RSI of 45.92.
On May 01st, 2017, Neovasc announced that it will release its financial results for Q1 2017 on Wednesday, May 10th, 2017, after markets close. The Company will subsequently hold a conference call that same day at 4:30 p.m. ET, which will be hosted by Mr. Alexei Marko, CEO, and Mr. Chris Clark, CFO. A question-and-answer session will follow the corporate update. The complimentary research report on NVCN can be downloaded at:
Amsterdam, the Netherlands headquartered Wright Medical Group N.V.'s stock ended the day 0.32% higher at $28.20. A total volume of 1.57 million shares was traded, which was above their three months average volume of 1.16 million shares. The Company's shares have gained 8.71% over the previous three months and 22.72% on an YTD basis. The stock is trading 11.16% above its 200-day moving average. Additionally, shares of Wright Medical, which designs, manufactures, markets, and sells extremities and biologics products in the US, Europe, Middle East, Africa, and internationally, have an RSI of 30.56.
On April 11th , 2017, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Buy' to 'Neutral'.
On May 02nd, 2017, Wright Medical announced that it will present at the UBS Global Healthcare Conference on Tuesday, May 23rd, 2017, at the Grand Hyatt Hotel in New York, NY. Lance Berry, CFO, will present at 8:30 a.m. ET. A live audio webcast of the conference presentation, along with the accompanying presentation materials, will be available under the "Investor Relations" link of the Company's website. Register for free on Stock-Callers.com and get access to the latest PDF format report on WMGI at:
Shares in Eden Prairie, Minnesota headquartered Sunshine Heart Inc. recorded a trading volume of 1.26 million shares, which was above their three months average volume of 679,320 shares. The stock ended Friday's session 6.42% lower at $0.74. The Company's shares have surged 111.17% since the start of this year. The stock is trading below its 200-day moving average by 56.08%. Furthermore, shares of Sunshine Heart, which develops cardiac and coronary disease products primarily in the US, have an RSI of 22.59.
On May 05th, 2017, Sunshine Heart announced that on May 04th, 2017, the Company was formally notified by NASDAQ that it has regained compliance with the minimum stockholders' equity requirement and is in compliance with all other applicable requirements for listing on The NASDAQ Capital Market. As a result of the foregoing, the NASDAQ listing matter has been closed. Download your free research report on SSH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA